Alessandra Di Bacco

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Philippe Moreau, Tamás Masszi, Norbert Grząśko et al. · New England Journal of Medicine · 2016 · 1K citations · Full text

<i>FGFR2</i> -Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival

Kaiko Kunii, Lenora J. Davis, Julie Gorenstein et al. · Cancer Research · 2008 · 264 citations

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study

Shaji Kumar, Jesús G. Berdeja, Rubén Niesvizky et al. · The Lancet Oncology · 2014 · 260 citations

Hematological Malignancy, Medicine, Hematology +10

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

Paul G. Richardson, Rachid Baz, Michael Wang et al. · Blood · 2014 · 200 citations · Full text

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

Shaji Kumar, William Bensinger, Todd M. Zimmerman et al. · Blood · 2014 · 192 citations · Full text